Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig, Dana Yehudai-Ofir, Boaz Nachmias, Hazim Khatib, Arnon Haran, Shlomzion Aumann

Blood (2024) 144 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2024-204627

Published: 2024

Journal Articles

UBE2E3 Supports Survival of Leukemia Stem Cells By Regulation of Polycomb Repression Complex (PRC) 1.1

Vika Miller, Ayat Hija, Mohamed Abdal-Rhaman, Noa Gross Even-Zohar, Michal Saltsman, Aaron Botham, Arnon Haran, Shlomzion Aumann, Vladimir Vainstein, Moshe E Gatt, Brian Raught, Aaron D Schimmer, Boaz Nachmias

Blood (2024) 144 (Supplement 1): 5714.

https://doi.org/10.1182/blood-2024-193438

Published: 2024

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Arnon Haran, Noa Gros Even-Zohar, Eyal Lebel, Shlomzion Aumann, Adir Shaulov, Moshe E Gatt, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2023-187241

Published: 2023

Journal Articles

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Vladimir Vainstein, Arnon Haran, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2023-179194

Published: 2023

Journal Articles

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Itay Falicovich, Boaz Nachmias, Eran Zimran, Adir Shaulov, Moshe E Gatt, Polina Stepensky, Sigal Grisariu Greenzaid, Batia Avni

Blood (2022) 140 (Supplement 1): 12876–12877.

https://doi.org/10.1182/blood-2022-164586

Published: 2022

Journal Articles

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion

Blood (2022) 140 (Supplement 1): 11947–11948.

https://doi.org/10.1182/blood-2022-159881

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

Journal Articles

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Rachel Burstein, Adir Shaulov, Dina Ben Yehuda, Boaz Nachmias, Moshe E Gatt, Ariel Aviv

Blood (2022) 140 (Supplement 1): 10793.

https://doi.org/10.1182/blood-2022-162541

Published: 2022

Journal Articles

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic

Shlomzion Aumann, Uria Tsubary, Sarah Israel, Dina Ben Yehuda, David Lavie, Neta Goldschmidt, Vladimir Vainstein, Diana Libster, Revital Saban, Adir Shaulov, Batia Avni, Boaz Nachmias, Sigal Grisariu, Ora Paltiel, Moshe Gatt, Eran Zimran

Blood (2021) 138 (Supplement 1): 4088.

https://doi.org/10.1182/blood-2021-148512

Published: 2021

Journal Articles

Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma

Eyal Lebel, Neta Goldschmidt, Tali Siegal, MD, Alexander Lossos, MD, Moshe Gatt, MD, Alexander Gural, MD, Adir Shaulov, MD, Revital Saban, MD, David Lavie, MD, Boaz Nachmias, MDPhD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-140949

Published: 2020

Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-135858

Published: 2020

Journal Articles

IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells

Boaz Nachmias, MDPhD, Veronique Voisin, PhD, Geethu Emily Thomas, PhDMSc,BSc, Dilshad H. Khan, Rose Hurren, BSc, Aaron Botham, Xiaoming Wang, Neil Maclean, Ayesh K Seneviratne, BSc, MSc, Changjiang Xu, Jonathan St-Germain, Andrea Arruda, MSc, Elias Orouji, Liran I. Shlush, MD, Mark D. Minden, Brian Raught, Gary D Bader, Aaron D Schimmer, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134787

Published: 2020

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Boaz Nachmias, MD PhD, Geremy Godefroy, MD, Chezi Ganzel, MD, Neta Goldschmidt, MD, Eyal Rozenbach, MD, Rachel Bar-Shalom, MD, Diana Libster, MD, Vladimir Vainstein, MD

Blood (2019) 134 (Supplement_1): 5358.

https://doi.org/10.1182/blood-2019-121473

Published: 2019

Journal Articles

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

Boaz Nachmias, MD PhD, Veronique Voisin, PhD, Rose Hurren, BSc, Xioaming Wang, Neil Maclean, G. Wei Xu, Ayesh K Seneviratne, BSc, MSc, Changjiang Xu, Gary D Bader, Liran I. Shlush, MD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2530.

https://doi.org/10.1182/blood-2019-122284

Published: 2019

NARROW

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

UBE2E3 Supports Survival of Leukemia Stem Cells By Regulation of Polycomb Repression Complex (PRC) 1.1

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic

Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only